Starling Oncology, Inc. Deferred Federal Income Tax Expense (Benefit)
Starling Oncology, Inc. (STLN) reported Deferred Federal Income Tax Expense (Benefit) of -$32.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-03-12
- Starling Oncology, Inc. deferred federal income tax expense (benefit) for fiscal 2025 was -$32.00K.
- Starling Oncology, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Starling Oncology, Inc. deferred federal income tax expense (benefit) for fiscal 2023 was $2.00K.
- Starling Oncology, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was -$135.00K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$32.00K 10-K · filed 2026-03-12 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 | |
| 2023-12-31 | $2.00K 10-K · filed 2025-03-26 | |
| 2022-12-31 | -$135.00K 10-K · filed 2024-03-28 | |
| 2021-12-31 | -$904.00K 10-K · filed 2023-03-16 | |
| 2020-12-31 | -$919.00K 10-K · filed 2022-03-11 | $101.68K 10-K · filed 2021-03-30 |
| 2019-12-31 | $483.00 10-K/A · filed 2021-12-14 |